Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Makaleler > Tam Makale · 2017
Yazarlar: M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, Minckwitz von, SKL Chia, J Mansi, CH Barrios, M Gnant, Z Tomaševic, N Denduluri, R Šeparovic, Erhan GÖKMEN, A Bashford, Borrego Ruiz, SB Kim, EH Jakobsen, A Ciceniene, K Inoue, F Overkamp, JB Heijns, AC Armstrong, JS Link, AA Joy, R Bryce, A Wong, S Moran, B Yao, F Xu, A Auerbach, M Buyse, A Chan, Study ExteNET
The Lancet Oncology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2017, cilt 18, ss 1688-1700